D&D Pharmatech said Monday that its GLP-1/glucagon dual agonist DD01 met the primary endpoint in a U.S. phase 2 study in ...

A 16-month-long government-doctor conflict is unable to find a way out. The hope that a change in political power will soon ...

Samsung Bioepis and its European partner Biogen have been dealt a legal blow in Germany after a higher court ruled that ...

Just because you can't hear doesn't mean you can't sing.Big Ocean, the world's first deaf idol group, is proof of this.

Patients with urothelial carcinoma are increasingly abandoning treatment. New drugs are being developed, but health insurance ...

A mobile game-based digital therapy has been shown to help improve social skills in adolescents with autism spectrum disorder ...

Celltrion has picked up additional approvals from the FDA and Health Canada for its biosimilar to Janssen’s Stelara, Steqeyma ...

Takeda Korea has launched Fruzaqla (fruquintinib), a once-daily oral treatment for metastatic colorectal cancer (mCRC), ...

Yuhan Corp. is making an early case for its allergy biologic YH35324 in chronic spontaneous urticaria (CSU), the medical term ...

Samsung Biologics has officially launched a new organoid-based drug screening platform, “Samsung Organoids,” as part of its ...

Korea-based CDMO Binex has secured a fresh manufacturing deal with Celltrion to produce drug substances for two clinical-stage biosimilar candidates, the company said Monday.Under the contract, Binex ...

A research team at Seoul National University Bundang Hospital (SNUBH) recently published a study demonstrating that the ...